The Treatment of Acute Leukaemia with 6-Mercaptopurine

  • F. G. J. Hayhoe


The recently introduced purine antimetabolite, 6-mercaptopurine, has been in clinical therapeutic trials in acute leukaemia at several centres in the last three years. The reports of such authors as Burchenal et al (1953), Hall et al (1954), Fountain (1955), and our own earlier experience (Hayhoe and Whitby 1955) have demonstrated that this substance is of potential value in three chief respects.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Burchenal, J. H., M. L. Murphy, R. R. Ellison, M. P. Sykes, T. C. Tan, L. A. Leone, D. A. Karnofsky, L. F. Craver, H. W. Dargeon, and C. P. Rhoads: Clinical evaluation of a new antimetabolite, 6-mercaptopurine in the treatment of leukaemia and allied diseases. Blood 8, 965–999 (1953).PubMedGoogle Scholar
  2. Fountain, J. R.: Treatment of leukaemia and allied disorders with 6-mercaptopurine. Brit. Med. J. 1, 1119 (1955).PubMedCrossRefGoogle Scholar
  3. Hall, B H, M. D. Richards, F. M. Willet and T. V. Feichtmeir: Clinical experience with 6-mercaptopurine in human neoplasia. Ann. N. Y. Acad. Sci. 60, 374–384 (1954).PubMedCrossRefGoogle Scholar
  4. Hayhoe, F. G. J., and L. Whitby: The Management of Acute Leukaemia in Adults. Brit. J. Haematol. 1, 1–19 (1955).CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1956

Authors and Affiliations

  • F. G. J. Hayhoe
    • 1
  1. 1.Cambridge UniversityEngland

Personalised recommendations